Mary Pan

Mary Gunn is a Chinese American scientist and the Chief Operating Officer of Health Decisions, a 30-year-old biotechnology and diagnostics service provider in R&D with a focus on women’s health. Gunn has a PhD in Psychology, MBA from Instituto Empresa and Brown University, LLM in Medical Ethics and Law from the University of Edinburgh, BA in Psychology, BA in Economics, and master’s in International Relations from Freie Universität Berlin.

Gunn is an executive-level scientist with 25 years of experience including as COO and GM of private and public biotechnology, medical technology, and CRO companies, overseeing up to 38 countries, 4200 employees, and a $1.6 Billion portfolio in pharmaceuticals (Pfizer), biotechnology (Crucell), medical devices/diagnostics (Becton Dickinson), and Clinical Research Organizations (ICON Plc). Therapeutic areas of expertise include women's health, oncology, autoimmune disease, neurology, vaccines/pandemic planning, and diagnostics. Her career experience is in building and operating companies, fundraising, increasing sales/productivity, and turning around difficult situations through in-depth understanding of drug/device development and their commercialization, as well as global business expertise, having been based out of Europe (UK, Germany, Switzerland), Asia (China, Singapore), and the USA.

Gunn serves on the board of a startup cell therapy company, SpotArt Foundation, is an industrial advisor to private equity, and was elected to the Advisory Board of University Planning for Brown University. She was also a founder of the first medical device trade association based out of Asia (APACMed). Gunn served as the President of Alumni for University of Edinburgh and Brown University, where she was a President’s Scholar and an Eve and Simon Colin Foundation Scholar.